Company Overview
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company that leverages its immunology expertise to target the CD40 Ligand (CD40L) pathway, aiming to develop therapies for protecting transplanted organs, preventing rejection, and treating amyotrophic lateral sclerosis. The company functions within the Healthcare sector and specifically the Biotechnology industry, positioning itself to address critical unmet needs in organ transplantation and neurodegenerative disease management. As of the latest reporting period, the firm maintains a market capitalization of $232.52M and employs a workforce of 33 individuals. The combination of a market cap in the low hundreds of millions and zero reported revenue indicates that Eledon is a capital-intensive entity in the early phases of commercialization or clinical development, where value is derived primarily from intellectual property and pipeline potential rather than current sales performance.
Financial Health
The company reports a net income of $-45,617,000 for the trailing twelve months, while revenue and EBITDA figures are listed as unavailable or effectively zero in the provided data. The substantial gap between negligible revenue and significant negative net income reveals a cost structure dominated by research and development expenses typical of clinical-stage biotechs, where operating costs far exceed current sales. Free cash flow stands at $-33,657,876, indicating that the company is burning cash to fuel its development programs and has limited immediate financial flexibility to fund operations without external capital raises. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, reflecting the absence of commercial sales volume that would generate a positive contribution to these specific profitability layers. On the liability side, Eledon holds $133.34M in cash against only $641,000 in debt, supported by a debt-to-equity ratio of 0.47, which suggests a balance sheet that is highly conservative rather than leveraged. The current ratio is an exceptional 7.40, indicating that the company possesses a robust buffer of liquid assets relative to its short-term obligations and is well-positioned to weather periods of negative operating cash flow. Return on Equity is -35.8% and Return on Assets is -30.0%, metrics that reveal management is currently deploying capital to grow the enterprise rather than generating immediate shareholder returns, a common characteristic of companies in the biotechnology sector prior to product approval.
Valuation Assessment
Valuation multiples for Eledon show a trailing P/E ratio of N/A due to negative earnings, while the forward P/E is calculated at -3.63, a figure that implies the market is pricing in future earnings expectations that are not yet realized in the current financial statements. The price-to-book ratio stands at 1.61, indicating that the market values the company at 61% above its net asset value, a premium often attributed to the intangible value of the clinical pipeline and proprietary technologies. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are listed as N/A, suggesting that traditional sales-based or earnings-based valuation models are not applicable to a pre-revenue biotechnology firm at this stage of development. Regarding price action, the stock has traded between a 52-week low of $1.35 and a 52-week high of $4.60, providing a clear historical range for assessing current entry points relative to recent volatility. The beta value of 0.96 indicates that the stock's price volatility moves in tandem with the broader market, lacking the significant amplification or dampening often seen in small-cap biotechnology equities.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, as the company has not yet generated sufficient commercial revenue to calculate meaningful growth rates. Consequently, there is no data to determine whether earnings are growing faster or slower than revenue, as both metrics remain in the developmental phase of the business lifecycle. Eledon Pharmaceuticals does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company reinvests all available resources and cash reserves back into its research and development efforts rather than distributing income to shareholders. The overall growth and income profile is defined by a focus on capital allocation toward clinical progression and regulatory approval, with the potential for significant future expansion contingent upon the successful commercialization of its CD40L pathway therapies.